TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of participants who accepted a rapid health screening/HIV test
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants who accepted the health screening/HIV test after a focus group
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Average Daily Hours of ON-time Without Troublesome Dyskinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Level of Strongyloides Serology as Measured by ELISA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anxiety score increase
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Concentration of ghrelin in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total Mayo score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Placebo-corrected change in HR-corrected QTcF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severe Impairment Battery (SIB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of ASTX660
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of ASTX660
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of midazolam and 1-hydroxyl midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of midazolam and 1-hydroxyl midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory Drive
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to sustained improvement in clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of all cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Post-procedural strokes and ischemic or hemorrhagic events causing motoric, language or cognitive compromise
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum observed plasma concentration of GLPG1690
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach maximum observed plasma concentration of GLPG1690
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of the last quantifiable plasma concentration of GLPG1690
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Rates of Intraocular Pressure (IOP) Spikes 30mm of Mercury (mmHg) or Greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Mean Percent Endothelial Cell Count (ECC) Change Preoperatively vs. Postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Bioequivalence based on AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complexity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in frailty Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in complexity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early colonizer load of S. sanguinis and S. mutant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in teamwork parameters
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Primary cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Frequency of CD3-CD16+CD56+ NK cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients experiencing complications
Endpoint domain: Adverse events/effects
Primary endpoint: modulation of pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With at Least 1 Solicited Injection Site Solicited Systemic Reactions Post-vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titers (GMTs) for the 3 Influenza Strains Pre- and Post-vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With at Least 1:40 Hemagglutination Inhibition Antibody Titer Post-Vaccination (Seroprotection)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With at Least a 4-Fold Rise in Hemagglutination Inhibition Antibody Titer Post-Vaccination (Seroconversion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Occupational Performance and Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Postoperative pain on visual analog score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Objective response rate (CR+PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Substance Use
Endpoint domain: Adverse events/effects
Primary endpoint: Ventilator Associated Respiratory Infection (VARI)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Minnesota Living with Heart Failure Questionnaire (MLWHF)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Acceptability of the SMARTCare intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Radioiodine uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Thyroglobulin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Seminal quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of Pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pedometer-derived step count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genomics response of hematopoietic cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Muscle dysfunction for oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle dysfunction for mitochondrial activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle dysfunction for apoptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle dysfunction for autophagy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: regional cerebral oxygen saturation (rSO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-Free-Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Absolute Bioavailability (F) of savolitinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative amount of AZD6094 (savolitinib) excreted (CumAe)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative amount of AZD6094 (savolitinib) excreted as a percentage of the administered dose (CumFe)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Verbs Per Minute (VPM) in Speech Sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale Subjective Rating of Drug Effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frailty index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale - Back Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-Reported Outcome Measurement Information System (PROMIS) - Physical Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Force Applied and Pressure Distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rating of surgical conditions during the abdominal phase of the operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Successful Sedation of Subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant GI Symptom Burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in microbiota alpha-diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in caregiver burden severity
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Change in Quality of life status
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in liver fat scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in liver stiffness scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in stool consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Biomarkers of inflammation and oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Overall Response Rate (ORR) Per RECIST v1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral performances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Mutational Burden (TMB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Infusion rate following intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in bioburden (specifically MRSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in alcohol abuse problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cannabis abuse problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cocaine abuse problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-reported physical intimate partner violence against women
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in self-reported psychological intimate partner violence against women
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in risk of recidivism
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Lachnospiraceae bacteria in stools
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pediatric anxiety score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in parent anxiety score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall Parental Satisfaction with the pre-operative process
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in post-operative behavior as assessed by the parent
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diagnostic performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pharmacokinetics (PK) of pracinostat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 100% Occlusion of the Aneurysm Without Clinically Significant Stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurologic Death or Major Ipsilateral Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Neuroplasticity of the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: changes in skin cooling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Time of Glucose Concentration Within the Target Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity to stimulation rate change at threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discrimination of stimulation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vena Contracta Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete Response (CR) / Complete Response with incomplete blood count recovery (CRi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Probing Pocket Depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Sites as Indicated by Reduction in Inflammation as Assessed by Clinical Attachment Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Bleeding Sites Per Participant as Assessed by Bleeding on Probing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in tic severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diversity of the lungs and upper airways microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety and tolerability of PIF-1
Endpoint domain: Adverse events/effects
Primary endpoint: Raw Task Load Index (TLX) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change From Baseline in Erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean Change From Baseline in Dryness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean Change From Baseline in Skin Overall Comfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Knowledge about the DNR order
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Symptoms of the Common Cold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of time sensor glucose levels are >250 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Variation in the performance of Flexibility test of the upper limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical success rate of periradicular repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum dose
Endpoint domain: Adverse events/effects
Primary endpoint: Effect on tumor vasculature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Symptomatic Intracranial Hemorrhage (sICH) Within 36 Hours of Treatment Onset
Endpoint domain: Adverse events/effects
Primary endpoint: Modified Rankin Scale (mRS) Score <1 or Return to mRS Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma arginase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximal Platelet Aggregation (MPA%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Soft tissue inflammatory reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percent of Participants With Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Events When Study Drug Infusion Was Stopped Early
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Monthly Adherence to Inhaled Corticosteroid Regimen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of Grade 2 or Greater Gastrointestinal Toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Point Prevalence Tobacco Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Dose Modifications due to Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Computerised cognitive assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Balance assessment (BESS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stiffness index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reflective index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: clinical response of the disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change In Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Frequency of vaso-occlusive and cerebral complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 25(OH)D Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Gadolinium-enhancing T1 Lesions Per MRI Scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Plasma concentration of Factor XII
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of p.Thr328Lys mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Videocapillaroscopy result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saliva cotinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fagerstrom Test for Nicotine Dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily profile of blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Positive and Negative Symptom Scale (PANSS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preferences regarding place of care and place of death met
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Percentage of Participants Achieving ACR50 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recidivism - Self Report of undetected crimes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recidivism - Self Report of Arrests
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recidivism - Official Records of arrests
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Substance Dependence symptoms - Texas Christian University (TCU) measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV Risk Behavior - Sex and Intravenous Drug Use (IDU) - TCU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tooth or tooth replacement survival
Endpoint domain: Mortality/survival
Primary endpoint: Oral health related quality of life: OHIP-14
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of interaction between HFDS and anticancer drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activated coagulation time safety coverage rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total daily dose of fentanyl and propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in muscle strength (kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Growth markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Incidence Rates of Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Incidence Rates of Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Incidence Rates of Deaths
Endpoint domain: Mortality/survival
Primary endpoint: mean change from baseline of visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time profile from time zero extrapolated to infinite time (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atabecestat-Specific T-cell Mediated Inflammatory Immune Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum erythropoietin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in blood pressure during anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in heart rate during anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in respiratory rate during anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Homocysteine serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: First variceal bleed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes